Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION: Tepotinib in Advanced NSCLC With MET Alterations
NCT02864992Phase 2Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Sep 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by EMD Serono. Started Sep 2016; status: active, not recruiting.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02864992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864992.